CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Alpha-linolenic enriched dietbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00410020
NCT00410020Phase 2Completed

Secondary Prevention of Atrial Fibrillation With an Alpha-Linolenic Enriched Diet : a Randomized Study

Assistance Publique - Hôpitaux de Paris·interventional·Posted Dec 12, 2006·Updated Dec 12, 2006

In Brief

A Phase 2 clinical trial evaluating Alpha-linolenic enriched diet for Atrial Fibrillation and Diet Therapy. Completed, across 3 sites.

Detailed Summary

An alpha linolenic acid (ALA) rich diet in the Lyon Diet Heart Study reduced sudden cardiac deaths possibly by reducing cardiac arrhythmias and ventricular fibrillation (Lancet 1994). Since then, there has been a growing interest in ALA, ω-3 fatty acid family precursor, as a cardioprotective nutrient. Much of the interest has focused on the potential antiarrhythmic effect of longer chain ω-3 fatty acids, DHA and EPA, derived from fish. We therefore concluded it important to test wether vegetable source ω-3 also had antiarrhythmic effects, as shown in animals by Leaf and McLennan, since this might also explain the beneficial effects seen on cardiovascular mortality in the Lyon Diet Heart Study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2006
Enrollment StartJun 1, 1999
Study CompletionJun 1, 2003
TodayJul 2, 2026
Posted 19.6 years ago

Interventions

Alpha-linolenic enriched dietbehavioral